References
1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA Cancer J Clin 70:7-30, 2020
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER Research Limited-Field DATA, 21 Registries, Nov 2020 Sub (2000-2018)- Linked to County Attributes- Time Dependent (1990-2018)- Income/ Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission.,
3. Amadeo B, Penel N, Coindre JM, et al: Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM). BMC Cancer 20:190, 2020
4. Gatta G, Capocaccia R, Botta L, et al: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 18:1022-1039, 2017
5. Whelan J, McTiernan A, Cooper N, et al: Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer 131:E508-517, 2012
6. de Pinieux G, Karanian M, Le Loarer F, et al: Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One 16:e0246958, 2021
7. Mirabello L, Troisi RJ, Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531-1543, 2009
8. Hameed M, Mandelker D: Tumor Syndromes Predisposing to Osteosarcoma. Adv Anat Pathol 25:217-222, 2018
9. Mirabello L, Zhu B, Koster R, et al: Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncol 6:724-734, 2020
10. Jawad MU, Cheung MC, Min ES, et al: Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer 115:3526-3536, 2009
11. Turc-Carel C, Aurias A, Mugneret F, et al: Chromosomes in Ewing’s sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 32:229-238, 1988
12. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al: A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6:146-151, 1994
13. Tirode F, Surdez D, Ma X, et al: Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 4:1342-1353, 2014
14. Brohl AS, Patidar R, Turner CE, et al: Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet Med 19:955-958, 2017
15. Abbott D, O’Brien S, Farnham JM, et al: Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. Cancer Med 8:7924-7930, 2019
16. Grunewald TGP, Cidre-Aranaz F, Surdez D, et al: Ewing sarcoma. Nat Rev Dis Primers 4:5, 2018
17. Miettinen M, Felisiak-Golabek A, Luina Contreras A, et al: New fusion sarcomas: histopathology and clinical significance of selected entities. Hum Pathol 86:57-65, 2019
18. Antonescu CR, Owosho AA, Zhang L, et al: Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol 41:941-949, 2017
19. Cohen-Gogo S, Cellier C, Coindre JM, et al: Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: a clinical, radiological and pathological retrospective study from the Societe Francaise des Cancers de L’Enfant. Pediatr Blood Cancer 61:2191-2198, 2014
20. Dahlin DC, Coventry MB: Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am 49:101-110, 1967
21. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-1606, 1986
22. Souhami RL, Craft AW, Van der Eijken JW, et al: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350:911-917, 1997
23. Bramwell VH, Burgers M, Sneath R, et al: A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10:1579-1591, 1992
24. Lewis IJ, Nooij MA, Whelan J, et al: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112-128, 2007
25. Marina NM, Smeland S, Bielack SS, et al: Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17:1396-1408, 2016
26. Anderson PW, P.; Lazarte, T.; Gore, L.; Salvador, L. & Salazar-Abshire, M.: Outpatient chemotherapy, family-centered care, electronic information, and education in adolescenets and young adults with osteosarcoma. Clinical Oncology in Adolescents and Young Adults. 3:1-11, 2013
27. Smeland S, Bielack SS, Whelan J, et al: Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109:36-50, 2019
28. Jeys LM, Grimer RJ, Carter SR, et al: Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol 14:2887-2895, 2007
29. Kim MS, Lee SY, Lee TR, et al: Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol 20:955-960, 2009
30. Song WS, Jeon DG, Kong CB, et al: Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma. Ann Surg Oncol 18:1710-1716, 2011
31. Moore C, Eslin D, Levy A, et al: Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer 55:1096-1102, 2010
32. Bielack SS, Smeland S, Whelan JS, et al: Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol 33:2279-2287, 2015
33. Duffaud F, Digue L, Mercier C, et al: Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer 39:2050-2057, 2003
34. Kempf-Bielack B, Bielack SS, Jurgens H, et al: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559-568, 2005
35. Bielack SS, Kempf-Bielack B, Branscheid D, et al: Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27:557-565, 2009
36. Palmerini E, Torricelli E, Cascinu S, et al: Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? Pediatr Blood Cancer 66:e27792, 2019
37. Bacci G, Briccoli A, Longhi A, et al: Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44:748-755, 2005
38. Briccoli A, Rocca M, Salone M, et al: Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 104:1721-1725, 2005
39. Matsubara EM, T.; Koga, T.; Shibata, H.; Ikeda, K.; Shiraishi, K. & Suzuki, M.: Metastasectomy of pulmonary metastases from osteosarcoma: Prognostic factors and indication for repeat metastasectomy. Journal of Respiratory Medicine, 2015
40. Treasure T, Fiorentino F, Scarci M, et al: Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data. BMJ Open 2, 2012
41. Treasure T, Milosevic M, Fiorentino F, et al: Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax 69:946-949, 2014
42. Ferrari S, Briccoli A, Mercuri M, et al: Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 21:710-715, 2003
43. Palmerini E, Setola E, Grignani G, et al: High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. Cells 9, 2020
44. Casali PG, Bielack S, Abecassis N, et al: Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv79-iv95, 2018
45. Burgert EO, Jr., Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol 8:1514-1524, 1990
46. Nesbit ME, Jr., Gehan EA, Burgert EO, Jr., et al: Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664-1674, 1990
47. Miser JS, Kinsella TJ, Triche TJ, et al: Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191-1198, 1987
48. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003
49. Paulussen M, Craft AW, Lewis I, et al: Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment–cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26:4385-4393, 2008
50. Le Deley MC, Paulussen M, Lewis I, et al: Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 32:2440-2448, 2014
51. Womer RB, Daller RT, Fenton JG, et al: Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcomas and soft tissue sarcomas in children. Eur J Cancer 36:87-94, 2000
52. Womer RB, West DC, Krailo MD, et al: Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148-4154, 2012
53. Anderton J, Moroz V, Marec-Berard P, et al: International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. Trials 21:96, 2020
54. Brennan BK, L.; Marec-Berard, P.; Martin-Broto, J.M.; Gelderblom, H.; Gasper, N.; Strauss, S.J.; Urgelles, A.S; Anderton, J.; Laurence, V.; et al. : Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randmoized trial (EE2012). . J. Clin. Oncol. 38:11500-11500, 2020
55. Schwartz CL, Wexler LH, Krailo MD, et al: Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children’s Oncology Group. Pediatr Blood Cancer 63:54-61, 2016
56. Mascarenhas L, Felgenhauer JL, Bond MC, et al: Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children’s Oncology Group. Pediatr Blood Cancer 63:493-498, 2016
57. Meyers PA, SR.; Slotkin, EK.; Dela Cruz, F. & Wexier, LH.: The addition of cycles of irinotecan/ temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES). Presented at the 2018 American Society of Clinical Oncology, May 20, 2018, 2018
58. Barker LM, Pendergrass TW, Sanders JE, et al: Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol 23:4354-4362, 2005
59. Cotterill SJ, Ahrens S, Paulussen M, et al: Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18:3108-3114, 2000
60. Stahl M, Ranft A, Paulussen M, et al: Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57:549-553, 2011
61. McCabe MK, L.; Khan, M.; Fenwick, N.; Dirksen, U.; Gaspar, N.; Kanerva, J.; Kuehne, T.; Longhi, A.; Luksch, R.; Mata, C.; Phillips, M.; Safwat, A.; Strauss, S.; Sundby Hall, K.; Valverde Morales, CM.; Westwood, AJ.; Winstanley, M.; Whelan, J. & Wheatley, K.: Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). Journal of Clinical Oncology 38:11502-11502, 2020
62. McCabe MM, V.; Khan, M.; Dirksen, U.; Evans, A.; Fenwick, N.; Gaspar, N.; Kanerva, J.; Kuhne, T.; Longhi, A.; Luksch, R.; Mata, C.; Phillips, M.; Sundby Hall, K.; Valverde Morales, CM.; Westwood, AJ.; Winstanley, M.; Whelan, J. & Wheatley, K.: Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. American Society of Clinical Oncology 37:11007- 11007, 2019
63. Ahmed SK, Randall RL, DuBois SG, et al: Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children’s Oncology Group. Int J Radiat Oncol Biol Phys 99:1286-1294, 2017
64. Andreou D, Ranft A, Gosheger G, et al: Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing’s Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial. Clin Orthop Relat Res 478:290-302, 2020
65. Schuck A, Ahrens S, Paulussen M, et al: Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 55:168-177, 2003
66. Foulon S, Brennan B, Gaspar N, et al: Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. Eur J Cancer 61:128-136, 2016
67. Casey DL, Meyers PA, Alektiar KM, et al: Ewing sarcoma in adults treated with modern radiotherapy techniques. Radiother Oncol 113:248-253, 2014
68. Gerrand C, Athanasou N, Brennan B, et al: UK guidelines for the management of bone sarcomas. Clin Sarcoma Res 6:7, 2016
69. Balamuth NJ, Womer RB: Ewing’s sarcoma. Lancet Oncol 11:184-192, 2010
70. Bernstein M, Kovar H, Paulussen M, et al: Ewing’s sarcoma family of tumors: current management. Oncologist 11:503-519, 2006
71. DuBois SG, Krailo MD, Gebhardt MC, et al: Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children’s Oncology Group. Cancer 121:467-475, 2015
72. Indelicato DJ, Keole SR, Shahlaee AH, et al: Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys 72:871-877, 2008
73. Donaldson SS: Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer 42:471-476, 2004
74. Ronchi L, Buwenge M, Cortesi A, et al: Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma. Anticancer Res 38:4977-4985, 2018
75. Meyers PA, Schwartz CL, Krailo MD, et al: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the Children’s Oncology Group. J Clin Oncol 26:633-638, 2008
76. Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004-2011, 2005
77. Meyers PA: Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 9:1035-1049, 2009
78. DeLaney TF, Park L, Goldberg SI, et al: Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 61:492-498, 2005
79. Stacchiotti S, Sommer J, Chordoma Global Consensus G: Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 16:e71-83, 2015
80. Riedel RF, Larrier N, Dodd L, et al: The clinical management of chondrosarcoma. Curr Treat Options Oncol 10:94-106, 2009
81. Ciernik IF, Niemierko A, Harmon DC, et al: Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 117:4522-4530, 2011
82. Oertel S, Blattmann C, Rieken S, et al: Radiotherapy in the treatment of primary osteosarcoma–a single center experience. Tumori 96:582-588, 2010
83. DeLaney TF, Liebsch NJ, Pedlow FX, et al: Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74:732-739, 2009
84. Ghosh KM, Lee LH, Beckingsale TB, et al: Indeterminate nodules in osteosarcoma: what’s the follow-up? Br J Cancer 118:634-638, 2018
85. Saifuddin A, Baig MS, Dalal P, et al: The diagnosis of pulmonary metastases on chest computed tomography in primary bone sarcoma and musculoskeletal soft tissue sarcoma. Br J Radiol:20210088, 2021
86. Cipriano C, Brockman L, Romancik J, et al: The Clinical Significance of Initial Pulmonary Micronodules in Young Sarcoma Patients. J Pediatr Hematol Oncol 37:548-553, 2015
87. Davison R, Hamati F, Kent P: What Effect Do Pulmonary Micronodules Detected at Presentation in Patients with Osteosarcoma Have on 5-Year Overall Survival? J Clin Med 10, 2021
88. Aryal A, Kumar VS, Shamim SA, et al: What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma? Clin Orthop Relat Res, 2021
89. Liu F, Zhang Q, Zhou D, et al: Effectiveness of (18)F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies. BMC Cancer 19:323, 2019
90. Palmerini E, Colangeli M, Nanni C, et al: The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging 44:215-223, 2017
91. Rothermundt C, Seddon BM, Dileo P, et al: Follow-up practices for high-grade extremity Osteosarcoma. BMC Cancer 16:301, 2016
92. Paioli A, Rocca M, Cevolani L, et al: Osteosarcoma follow-up: chest X-ray or computed tomography? Clin Sarcoma Res 7:3, 2017
93. Puri A, Gulia A, Hawaldar R, et al: Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. Clin Orthop Relat Res 472:1568-1575, 2014
94. Puri A, Ranganathan P, Gulia A, et al: Does a less intensive surveillance protocol affect the survival of patients after treatment of a sarcoma of the limb? updated results of the randomized TOSS study. Bone Joint J 100-B:262-268, 2018
95. Campbell KM, Shulman DS, Grier HE, et al: Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review. Pediatr Blood Cancer 68:e28807, 2021
96. Newman EN, Jones RL, Hawkins DS: An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer 60:1113-1117, 2013
97. Cesari M, Righi A, Colangeli M, et al: Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution. Pediatr Blood Cancer 66:e27653, 2019
98. Inagaki C, Shimoi T, Sumiyoshi Okuma H, et al: Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography. Med Oncol 36:58, 2019
99. Kasalak O, Glaudemans A, Overbosch J, et al: Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma? Skeletal Radiol 47:363-367, 2018
100. Kalus S, Saifuddin A: Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review. Eur Radiol 29:5700-5708, 2019
101. Oberlin O, Rey A, Desfachelles AS, et al: Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l’Enfant. J Clin Oncol 24:3997-4002, 2006
102. McTiernan A, Driver D, Michelagnoli MP, et al: High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing’s sarcoma family of tumours. Ann Oncol 17:1301-1305, 2006
103. Luksch R, Tienghi A, Hall KS, et al: Primary metastatic Ewing’s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol 23:2970-2976, 2012
104. Ladenstein R, Potschger U, Le Deley MC, et al: Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 28:3284-3291, 2010
105. Whelan J, Le Deley MC, Dirksen U, et al: High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol:JCO2018782516, 2018
106. Dirksen U, Brennan B, Le Deley MC, et al: High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol 37:3192-3202, 2019
107. Dirksen UB, V.; Brichard, B.; Butterfass-Bahloul, T.; Cyprova, S.; Faldum, A.; Gelderblom, H.; Hardes, J.; Hauser, P.; Havemann, L.; Hjorth, L.; Juergens, H.; Kanerva, J.; Kuehne, T.; Ladenstein, RL.; Raciborska, A.; Rascon, J.; Timmermann, B.; Ranft, A. & Koch, R, on behlaf of the Cooperative Ewing Sarcoma Study Group Ewing 2008.: Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: Report from the International Ewing 2008R3 trial. Journal of Clinical Oncology 38:11501-11501, 2020
108. Meyers PA, Krailo MD, Ladanyi M, et al: High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol 19:2812-2820, 2001
109. Yang X, Zhang L, Yang X, et al: Oncologic outcomes of pre- versus post-operative radiation in Resectable soft tissue sarcoma: a systematic review and meta-analysis. Radiat Oncol 15:158, 2020
110. Bedetti B, Wiebe K, Ranft A, et al: Local control in Ewing sarcoma of the chest wall: results of the EURO-EWING 99 trial. Ann Surg Oncol 22:2853-2859, 2015
111. Vogin G, Helfre S, Glorion C, et al: Local control and sequelae in localised Ewing tumours of the spine: a French retrospective study. Eur J Cancer 49:1314-1323, 2013
112. Bekelman JE, Schultheiss T, Berrington De Gonzalez A: Subsequent malignancies after photon versus proton radiation therapy. Int J Radiat Oncol Biol Phys 87:10-12, 2013
113. Merchant TE: Clinical controversies: proton therapy for pediatric tumors. Semin Radiat Oncol 23:97-108, 2013
114. Chung CS, Yock TI, Nelson K, et al: Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 87:46-52, 2013
115. Leroy R, Benahmed N, Hulstaert F, et al: Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. Int J Radiat Oncol Biol Phys 95:267-278, 2016
116. Rombi B, DeLaney TF, MacDonald SM, et al: Proton radiotherapy for pediatric Ewing’s sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 82:1142-1148, 2012
117. Sklar C: Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr:25-27, 2005
118. Critchley HO, Wallace WH: Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr:64-68, 2005
119. Gross E, Champetier C, Pointreau Y, et al: [Normal tissue tolerance to external beam radiation therapy: ovaries]. Cancer Radiother 14:373-375, 2010
120. Haie-Meder C, Mlika-Cabanne N, Michel G, et al: Radiotherapy after ovarian transposition: ovarian function and fertility preservation. Int J Radiat Oncol Biol Phys 25:419-424, 1993
121. Yamada Y, Lovelock DM, Yenice KM, et al: Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report. Int J Radiat Oncol Biol Phys 62:53-61, 2005
122. Nevelsky A, Borzov E, Daniel S, et al: Perturbation effects of the carbon fiber-PEEK screws on radiotherapy dose distribution. J Appl Clin Med Phys 18:62-68, 2017
123. Barnett JR, Gikas P, Gerrand C, et al: The sensitivity, specificity, and diagnostic accuracy of whole-bone MRI for identifying skip metastases in appendicular osteosarcoma and Ewing sarcoma. Skeletal Radiol 49:913-919, 2020
124. Theruvath AJ, Siedek F, Muehe AM, et al: Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. Radiology 296:143-151, 2020
125. Nicoli F, Saleh DB, Ragbir M, et al: Response to: Comment on ”Intraoperative Near-infrared Fluorescence (NIR) Imaging with Indocyanine Green (ICG) Can Identify Bone and Soft Tissue Sarcomas which May Provide Guidance for Oncological Resection”. Ann Surg, 2020
126. Laitinen MK, Parry MC, Albergo JI, et al: Is computer navigation when used in the surgery of iliosacral pelvic bone tumours safer for the patient? Bone Joint J 99-B:261-266, 2017
127. Tate R, Gerrand C, Hale J: Tibial turn-up procedure as an alternative to rotationplasty in a 4-year-old with osteosarcoma of the distal femur. J Pediatr Orthop B 24:50-55, 2015
128. Hebert JS, Rehani M, Stiegelmar R: Osseointegration for Lower-Limb Amputation: A Systematic Review of Clinical Outcomes. JBJS Rev 5:e10, 2017
129. Jeys LM, Thorne CJ, Parry M, et al: A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification. Clin Orthop Relat Res 475:842-850, 2017
130. Fujiwara T, Medellin MR, Sambri A, et al: Preoperative surgical risk stratification in osteosarcoma based on the proximity to the major vessels. Bone Joint J 101-B:1024-1031, 2019
131. Mumith A, Coathup M, Chimutengwende-Gordon M, et al: Augmenting the osseointegration of endoprostheses using laser-sintered porous collars: an in vivo study. Bone Joint J 99-B:276-282, 2017
132. Parry MC, Laitinen MK, Albergo JI, et al: Silver-coated (Agluna(R)) tumour prostheses can be a protective factor against infection in high risk failure patients. Eur J Surg Oncol 45:704-710, 2019
133. Bleyer A, Tai E, Siegel S: Role of clinical trials in survival progress of American adolescents and young adults with cancer-and lack thereof. Pediatr Blood Cancer 65:e27074, 2018
134. Ferrari A, Stark D, Peccatori FA, et al: Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE). ESMO Open 6:100096, 2021
135. Gaspar N, Marshall LV, Binner D, et al: Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Ann Oncol 29:766-771, 2018
136. Davis LE, Bolejack V, Ryan CW, et al: Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol 37:1424-1431, 2019
137. Duffaud F, Mir O, Boudou-Rouquette P, et al: Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20:120-133, 2019
138. Attia SB, V.; Ganjoo, KN.; George, S.; Agulnik, M.; Rushing, DA.; Loggers, ET.; Livingston, MB.; Wright, JA.; Chawla, SP.; Okuno, SH.; Reinke, DK.; Riedel, RF.; Davis, LE.; Ryan, CW. & Maki, RG.: A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. Presented at the ASCO, May 20, 2017
139. Duffaud FB, J.; Mir, O.; Chevreau, CM.; Boudou Rouquette, P.; Kalbacher, E.; Penel, N.; Perrin, C.; Laurence, V.; Bompas, E.; Saada-Bouzid, E.; Delcambre, C.; Bertucci, F.; Cancel, M.; Schiffler, C.; Monard, L.; Bouvier, C.; Vidal, C.; Gasper, N. & Chabaud, S.: LBA68 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Presented at the ESMO virtual conference 2020., 20 Sept 2020, 2020
140. Italiano A, Mir O, Mathoulin-Pelissier S, et al: Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 21:446-455, 2020
141. Xie L, Xu J, Sun X, et al: Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. Oncologist 24:e542-e550, 2019
142. Gaspar NBS, FJ.; Venkatramani, R.; Longhi, A.; Lervat, C.; Casanova, M.; Aerts, I.; Bielack, SS.; Entz-Werle, N.; Strauss, S.; He, C.; Thebaud, E.; Locatelli, F.; Morland, B.; Gallego Melcon, S.; Canete Nieto, A.; Marec-Berard, P.; Gambart, M.; Rossig, C. & Campbell- Hewson, Q.: Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to≤25 years with relapsed/refractory (r/r) osteosarcoma. Presented at the European Society for Medical Oncology (ESMO), 2019
143. Brenner JC, Feng FY, Han S, et al: PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res 72:1608-1613, 2012
144. Choy E, Butrynski JE, Harmon DC, et al: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14:813, 2014
145. Schafer ES, Rau RE, Berg SL, et al: Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children’s Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer 67:e28073, 2020
146. Chugh R, Ballman KV, Helman LJ, et al: SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer 127:1301-1310, 2021
147. Smith MA, Reynolds CP, Kang MH, et al: Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21:819-832, 2015
148. Engert F, Kovac M, Baumhoer D, et al: Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget 8:48794-48806, 2017
149. Holme H, Gulati A, Brough R, et al: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Sci Rep 8:10614, 2018
150. Jones DTW, Banito A, Grunewald TGP, et al: Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nat Rev Cancer 19:420-438, 2019
151. Tawbi HA, Burgess M, Bolejack V, et al: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493-1501, 2017
152. D’Angelo SP, Mahoney MR, Van Tine BA, et al: Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426, 2018
153. Paoluzzi L, Cacavio A, Ghesani M, et al: Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res 6:24, 2016
154. Sundara YT, Kostine M, Cleven AH, et al: Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother 66:119-128, 2017
155. Dobrenkov K, Ostrovnaya I, Gu J, et al: Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer 63:1780-1785, 2016
156. Wingerter A, El Malki K, Sandhoff R, et al: Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma. Cancers (Basel) 13, 2021
157. Mody R, Yu AL, Naranjo A, et al: Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group. J Clin Oncol 38:2160-2169, 2020
158. Erkizan HV, Kong Y, Merchant M, et al: A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med 15:750-756, 2009
159. Zollner SK, Selvanathan SP, Graham GT, et al: Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma. Sci Signal 10, 2017
160. Ludwig JF, NC.; Anderson, PM.; Macy, ME.; Riedel, RF.; Davis, LE.; Daw, NC.; Wulff, J.; Kim, A.; Ratan, R.; Baskin-Bey, ES.; Toretsky, JA.; Breitmeyer, JB. & Meyers, PA.: TK216 for relapsed/ refractory Ewing sarcoma: Interim phase 1/2 results. Journal of Clinical Oncology 39:11500-11500, 2021
161. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER Research Data, 9 Registries, Nov 2019 Sub (1975-2017)- Linked to County Attributes- Time Dependent (1990- 2017) Income/ Rurality, 1969- 2018 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission.
162. Joinpoint Regression Program, Version 4.6.0.0. April, 2018; Statistical Research and Applications Branch, National Cancer Institute. Statistical Research and Applications Branch, National Cancer Institute. Kim HJ, Fay MP, Feuer, EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19:335-351 (correction: 2001;20:655).
163. Granowetter L, Womer R, Devidas M, et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 27:2536-2541, 2009
164. Le Grange F: Advanced radiotherapy techniques: Improving outcomes in sarcoma., UCL (University College London), UCL Discovery., 2021
165. Gaspar NC, M.; Bautista Sirvent, FJ.; Venkatramani, R.; Morland, B.; Gambart, M.; Thebaud, E.; Strauss, S.; Locatelli, F.; Melcon, SG.; Canete, A.; Bielack, SS.; Rossig, C.; Aerts, I.; Marec-Berard, P.; Kraljevic, S.; Hayato, S.; He, C.; Dutcus, CE. & Campbell-Hewson, Q.: Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS). Journal of Clinical Oncology 36:11527-11527, 2018
166. Federico SM, Pappo AS, Sahr N, et al: A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer 137:204-213, 2020